DEF 14A: Calidi Biotherapeutics Seeks Stockholder Approval for Reverse Stock Split, Convertible Note Conversions, and Equity Purchase Agreement

Calidi Biotherapeutics is holding a special meeting to seek stockholder approval for a reverse stock split, the conversion of convertible notes, and a standby equity purchase agreement to enhance financial flexibility.

Summary

• Calidi Biotherapeutics is convening a special meeting of stockholders on June 6, 2024, to vote on several key proposals.
• The proposals include a reverse stock split at a ratio between 1-for-10 and 1-for-50, aimed at increasing the stock price and attracting investors.
• Stockholders will also vote on approving the issuance of common stock units related to the conversion of a $1.0 million convertible note and a $2.0 million convertible note, both potentially resulting in issuances exceeding 20% of outstanding shares.
• Additionally, the company seeks approval for a $25.0 million Standby Equity Purchase Agreement (SEPA), which could be increased to $50.0 million, also potentially leading to issuances exceeding 20% of outstanding shares.
• Finally, a proposal to adjourn the meeting, if necessary, to solicit additional proxies in favor of the reverse stock split is also on the agenda.
• The board believes these measures are essential for the company's financial stability and future capital-raising efforts.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is taking proactive steps to improve its financial position, there are inherent risks and potential dilution associated with the proposed actions. The need for these measures also suggests underlying financial challenges.

Positives

• The reverse stock split could increase the stock price, potentially attracting more investors and improving liquidity.
• Approval of the convertible note conversions and SEPA would provide the company with additional financial flexibility and access to capital.
• The company believes these measures are in the best interests of stockholders and will support future growth.

Negatives

• The reverse stock split may not increase the stock price over the long term and could decrease liquidity.
• Issuance of shares related to the convertible notes and SEPA will dilute existing stockholders' ownership.
• The market may view the reverse stock split negatively, potentially leading to a decrease in overall market capitalization.

Risks

• The reverse stock split may not achieve the desired increase in stock price.
• The company's need to raise capital could put downward pressure on the stock price.
• Failure to obtain stockholder approval for these proposals could limit the company's financial options.

Future Outlook

The company intends to raise capital through equity or debt financing to fund its current operations, but there is no assurance that such financing will be available on acceptable terms.

Management Comments

• The Board believes that a higher stock price, which may be achieved through a Reverse Stock Split, could help facilitate the Company's ability to raise new equity capital either through private fund-raising transactions or by accessing the public equity capital markets, to generally stimulate investor interest in the Company and help attract, retain, and motivate employees.
• The Board intends to effect the Reverse Stock Split only if it believes that a decrease in the number of shares outstanding is in the best interests of the Company and our stockholders and is likely to improve the trading price of our Common Stock and our ability to raise additional capital.

Industry Context

Many companies with low stock prices consider reverse stock splits to improve their market perception and attract institutional investors, which can lead to increased trading volume and liquidity.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies trading below listing requirements, similar to what happened with companies like Cytokinetics (CYTK) in the past.
• Standby Equity Purchase Agreements (SEPAs) are used by companies like Tonix Pharmaceuticals (TNXP) to secure funding, although they can lead to dilution.
• Convertible notes are frequently used in the biotech industry for short-term financing, similar to what Omeros Corporation (OMRS) has done in the past.

Stakeholder Impact

• Stockholders will experience potential dilution from the issuance of new shares.
• Employees may benefit from improved financial stability and capital raising.
• The company's ability to fund operations and research could be enhanced.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The Board will determine whether to implement the reverse stock split based on market conditions and the company's best interests.
• The company will proceed with the convertible note conversions and SEPA if the proposals are approved.

Key Dates

Keywords

reverse stock split, convertible note, SEPA, proxy statement, stockholder meeting, dilution, capital raising, NYSE American, common stock, warrants, Calidi Biotherapeutics